Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Current Liabilities: 2018-2025

Historic Total Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $6.0 million.

  • China SXT Pharmaceuticals' Total Current Liabilities fell 61.94% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 61.94%. This contributed to the annual value of $6.0 million for FY2025, which is 32.46% down from last year.
  • As of FY2025, China SXT Pharmaceuticals' Total Current Liabilities stood at $6.0 million, which was down 32.46% from $8.9 million recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Current Liabilities peaked at $18.6 million during FY2021, and registered a low of $6.0 million during FY2025.
  • Moreover, its 3-year median value for Total Current Liabilities was $8.9 million (2024), whereas its average is $9.8 million.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Total Current Liabilities surged by 51.50% in 2021 and then slumped by 38.59% in 2024.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Total Current Liabilities stood at $18.6 million in 2021, then fell by 7.85% to $17.1 million in 2022, then decreased by 15.33% to $14.5 million in 2023, then plummeted by 38.59% to $8.9 million in 2024, then tumbled by 32.46% to $6.0 million in 2025.